AlloVir (ALVR) Competitors $2.40 -0.21 (-8.05%) As of 07/15/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALVR vs. RNXT, RENB, ZIVO, QNTM, CRVO, AADI, BLUE, OSTX, VTVT, and DTILShould you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include RenovoRx (RNXT), Renovaro (RENB), ZIVO Bioscience (ZIVO), Quantum Biopharma (QNTM), CervoMed (CRVO), Aadi Bioscience (AADI), bluebird bio (BLUE), OS Therapies (OSTX), vTv Therapeutics (VTVT), and Precision BioSciences (DTIL). These companies are all part of the "pharmaceutical products" industry. AlloVir vs. Its Competitors RenovoRx Renovaro ZIVO Bioscience Quantum Biopharma CervoMed Aadi Bioscience bluebird bio OS Therapies vTv Therapeutics Precision BioSciences AlloVir (NASDAQ:ALVR) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings. Do analysts prefer ALVR or RNXT? RenovoRx has a consensus price target of $7.25, indicating a potential upside of 457.69%. Given RenovoRx's stronger consensus rating and higher probable upside, analysts plainly believe RenovoRx is more favorable than AlloVir.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00RenovoRx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor ALVR or RNXT? In the previous week, RenovoRx had 2 more articles in the media than AlloVir. MarketBeat recorded 2 mentions for RenovoRx and 0 mentions for AlloVir. RenovoRx's average media sentiment score of 0.94 beat AlloVir's score of 0.00 indicating that RenovoRx is being referred to more favorably in the news media. Company Overall Sentiment AlloVir Neutral RenovoRx Positive Which has stronger earnings & valuation, ALVR or RNXT? RenovoRx has higher revenue and earnings than AlloVir. RenovoRx is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlloVirN/AN/A-$190.42M-$20.23-0.12RenovoRx$40K1,188.53-$8.81M-$0.40-3.25 Is ALVR or RNXT more profitable? AlloVir's return on equity of -71.03% beat RenovoRx's return on equity.Company Net Margins Return on Equity Return on Assets AlloVirN/A -71.03% -61.27% RenovoRx N/A -119.58%-88.01% Do institutionals & insiders believe in ALVR or RNXT? 66.1% of AlloVir shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 32.1% of AlloVir shares are held by insiders. Comparatively, 9.1% of RenovoRx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, ALVR or RNXT? AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, RenovoRx has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. SummaryRenovoRx beats AlloVir on 9 of the 14 factors compared between the two stocks. Get AlloVir News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVR vs. The Competition Export to ExcelMetricAlloVirBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.10M$269.90M$5.51B$9.31BDividend YieldN/AN/A4.25%4.08%P/E Ratio-0.12N/A28.1519.68Price / SalesN/A431.06439.01100.25Price / CashN/A22.4435.5357.53Price / Book0.089.708.235.67Net Income-$190.42M-$110.10M$3.23B$257.51M7 Day Performance-5.88%-4.84%-0.56%-0.16%1 Month Performance-10.11%11.18%6.67%9.89%1 Year Performance-87.09%20.43%27.00%15.08% AlloVir Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVRAlloVirN/A$2.40-8.0%N/A-87.3%$12.10MN/A-0.12110High Trading VolumeRNXTRenovoRx2.2362 of 5 stars$1.32-2.9%$7.25+449.2%+4.0%$49.74M$240K-3.306Positive NewsRENBRenovaro1.8762 of 5 stars$0.30+2.6%N/A-76.1%$49.72MN/A-0.3920ZIVOZIVO BioscienceN/A$13.00+8.4%N/A+59.6%$49.62M$15.85K-2.6610Gap UpQNTMQuantum BiopharmaN/A$16.56-2.9%N/AN/A$49.60MN/A-1.04N/ACRVOCervoMed3.2675 of 5 stars$5.87+3.9%$27.63+370.6%-61.7%$49.17M$9.74M-2.694Positive NewsAADIAadi Bioscience0.3725 of 5 stars$1.99+5.9%$1.67-16.2%+16.9%$49.15M$25.07M-0.8740BLUEbluebird bio1.585 of 5 stars$4.97flat$44.60+797.4%N/A$48.67M$103.95M-0.13520OSTXOS Therapies2.2194 of 5 stars$1.73-5.5%$18.00+940.5%N/A$48.61MN/A-2.01N/AAnalyst ForecastVTVTvTv Therapeutics1.606 of 5 stars$15.10+0.2%$35.50+135.2%-30.3%$48.14M$1.02M-5.019DTILPrecision BioSciences4.2091 of 5 stars$4.31-0.7%$47.00+990.5%-56.5%$48.12M$68.70M-2.14200Gap Down Related Companies and Tools Related Companies RNXT Alternatives RENB Alternatives ZIVO Alternatives QNTM Alternatives CRVO Alternatives AADI Alternatives BLUE Alternatives OSTX Alternatives VTVT Alternatives DTIL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALVR) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
